Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Jan 24, 2019 (8 years ago)

BromSite (bromfenac ophthalmic solution)

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Bromfenac Ophthalmic Solution, 0.075% (Sterile 5 mL) may have a lack of sterility assurance.

Cause type: Sterility / contamination

A product that must be sterile could not be assured sterile, or was contaminated. A top reason for injectables, eye drops and IV products - loss of sterility assurance can lead to serious infections. All sterility / contamination recalls.

What was recalled

BromSite (bromfenac ophthalmic solution) 0.075%, 5 mL bottles, Rx Only, Distributed by : Sun Pharmaceutical Industries, Inc. Cranbury, NJ 08512, NDC 49708-754-41

Affected NDC 49708-0754-41

Compare with the code on your package — it is the most precise check available.

Drug: Bromfenac Category: Eye Drops & Ophthalmic

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Bromsite 0.075%
bromfenac
NDC 49708-0754
SODIUM .76 mg/mL Solution/ Drops
Ophthalmic
Sun Pharmaceutical Industries, Inc. Rx
Recalling firm
Sun Pharmaceutical Industries, Inc.
NDC code
49708-754-41
Origin
NJ, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0422-2019 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Bromfenac recalls

See all
Class II · Moderate risk

Bromfenac Ophthalmic Solution 0.07%

Failed Impurities/Degradation Specifications: out of specification at the time of testing i.e. 20th month stability testing.

Ongoing Impurity / degradation Alembic Pharmaceuticals, INC. NDC 62332-583-03 Recall number pending

Other recalls by Sun Pharmaceutical Industries, Inc.

All 2019 recalls
Class II · Moderate risk

Carbamazepine Tablets

CGMP Deviations; black spots found on tablets from burnt excipient during manufacturing

Ongoing cGMP deviation Sun Pharmaceutical Industries INC NDC 51672-4005-3 D-0770-2026
Class II · Moderate risk

Perampanel CIII Tablets

Labeling: Label Mix-up: 10mg Perampanel CIII tablet was found in a Perampanel CIII bottle labeled Perampanel 6 mg tablets.

Ongoing Labeling / mix-up Sun Pharmaceutical Industries INC NDC 51672-4206-6 D-0628-2026